SynthesisFrontiers in oncology2025
The dual role of circHIPK3 in cancer and its implications for multiple drugs resistance: a systematic review and computational approach.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Upregulation of a CircularInternational journal of molecular sciences · 2026Article
- Circular RNAs: Key Regulators of Tumor Metabolic Reprogramming and Clinical Translation.Oncology research · 2026Review
- Drug resistance in glioblastoma: Challenges, mechanisms and therapeutic strategies (Review).Molecular and clinical oncology · 2026Review
- Roles, mechanisms, and clinical implications of circHIPK3 in female malignancy: a comprehensive review.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: circHIPK3 role in cancer as oncogene or tumor suppressor is still debated, therefore, this study aimed to understand the dual role of this circRNA in different cancers. Furthermore, all available evidence of circHIPK3 interactions with sponged-miRNA and RBPs in oncological diseases were systematically gathered to better understand the its functional role in cancer. Methods: PubMed, BioMedCentral, Web of Science, Embase and Scopus databases were searched for articles published until October 2024, following the PRISMA guideline. In computational analysis, miRNAs' sponged target genes and RBPs were used for gene enrichment in KEGG, REACTOME and Gene Ontology, and TISSUES expression. miRTargetLink 2.0 was used to search for target genes, and STRING v.12.0 for gene enrichment. Results: circHIPK3 can regulate 33 miRNAs which regulate 399 target genes, and that were mainly enriched in major biological pathways important for cancer development and promoting. circHIPK3/miR-124-3p/miR-637/miR-338-3p are the most well documented interactions in cancers that may control MAPK, Jak/STAT3, Wnt/β-catenin, and PI3K/Akt signaling pathways. circHIPK3 regulates miRNAs that modulate genes responsible for chemoresistance, such as ATP-binding cassette and solute carrier transporters genes, and DNA repair genes. circHIPK3 has binding sites for RBPs, which participate mainly of RNA processing and control, and gene expression regulation. Finally, we believe that it has an onco-circRNA role in most cancers, except in bladder cancer, where it has a TS-circRNA function likely due to the microenvironment permeated by high amounts of hydrogen peroxide. Conclusion: circHIPK3 dysregulation is an important mechanism for cancer establishment, progression and chemoresistance making it an interesting molecule with a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.